What is the significance of comparing study doses in cancer-related anemia?
36,000 IU versus 40,000 IU rhEPO efficacy met non-inferiority criteria.[1] ↗
Human multi-center open-label randomized; cancer-related anemia
Dose comparison supports clinical medication optimization, cannot be extended to healthy individuals for enhancing exercise performance.
View the Article Title and Full Citation+
[Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial].
Chinese Journal of Oncology · Volume/Issue Year 2026
First published 2026-04-01 · PMID 42086522
DOI 10.3760/cma.j.cn112152-20250619-00280







